KEY TAKEAWAYS
- The study aimed to assess trilaciclib’s real-world impact on SN in ES-SCLC.
- The primary endpoint was to evaluate SN incidence during treatment.
- Researchers noticed that trilaciclib improved safety without affecting survival outcomes in ES-SCLC.
Trilaciclib has demonstrated significant reductions in severe neutropenia (SN) incidence compared to placebo plus carboplatin, etoposide, ± atezolizumab (PEA) in patients with extensive-stage small cell lung cancer (ES-SCLC). However, its real-world application remains underutilized. Joseph Elijah and the team aimed to assess the real-world effectiveness and safety of trilaciclib in ES-SCLC treatment to better understand its practical benefits in clinical settings.
Trilaciclib has demonstrated significant reductions in SN incidence compared to PEA in patients with ES-SCLC. However, its real-world application remains underutilized.
Joseph Elijah and the team aimed to assess the real-world effectiveness and safety of trilaciclib in ES-SCLC treatment to better understand its practical benefits in clinical settings.
They conducted a comprehensive analysis comparing trilaciclib + PEA (PEAT) to PEA in patients with ES-SCLC. This single-center study covered April 1, 2021, to July 31, 2022, for PEAT recipients and February 1, 2020, to February 28, 2021, for PEA recipients. The primary endpoint assessed was the incidence of SN after cycle 1 and throughout the treatment period, while secondary endpoints focused on myelopreservation and patient outcomes.
About 34 patients in the PEAT cohort and 44 patients in the PEA cohort were analyzed. Baseline characteristics were comparable, except for a higher median age (69 vs 64 years) and a greater proportion of males (64.7% vs 38.6%) in the PEAT group. The PEAT cohort exhibited a lower SN rate (3%) compared to the PEA cohort (18%), with statistical significance demonstrated on multivariate analysis (P = 0.015). Furthermore, the PEAT cohort showed significant reductions in red blood cell transfusion requirements (3% vs 23%; P = 0.02), grade 3-4 anemia (6% vs 25%; P = 0.03), and grade 3-4 thrombocytopenia (0% vs 11%; P = 0.045).
The study concluded that trilaciclib, in combination with PEA, significantly improved the safety profile by reducing SN and related complications without compromising survival outcomes in patients with ES-SCLC. These findings highlight the potential benefits of incorporating trilaciclib into real-world clinical practice to enhance patient care.
The study received open-access funding provided by Northeastern University Library.
Source: https://pubmed.ncbi.nlm.nih.gov/39215800/
Elijah J, Jain P, Holdsworth A, et al. (2024). “Trilaciclib use in extensive-stage small cell lung cancer (ES-SCLC): are clinical benefits seen in the real-world setting?” Support Care Cancer. 2024;32(9):622. Published 2024 Aug 31. doi:10.1007/s00520-024-08828-1
